Bone Biologics (BBLG) Accounts Payables (2013 - 2026)
Bone Biologics (BBLG) posted quarterly Accounts Payables of $417884.0 for Q4 2025, up 12.02% year-over-year from $373042.0 in Q4 2024, and up 25.46% quarter-over-quarter from $333081.0 in Q3 2025.
Powered by 
Analysis
Bone Biologics (BBLG) Accounts Payables (2013 - 2026) Analysis & Trends
Bone Biologics (BBLG) has reported Accounts Payables for 13 consecutive years, with $417884.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Accounts Payables rose 12.02% year-over-year to $417884.0; the TTM figure through Dec 2025 stood at $417884.0 (up 12.02% YoY), while the FY2025 annual figure was $417884.0, up 12.02% from the prior year.
- Accounts Payables rose to $417884.0 in Q4 2025 per BBLG's latest filing, from $333081.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $2.3 million in Q1 2023 and bottomed at $54913.0 in Q1 2022.
- Historically, Accounts Payables has averaged $478146.7 across 5 years, with a median of $290462.0 in 2025.
- Annual changes were most pronounced in 2023 — Accounts Payables jumped 4050.55% — and 2024, when it tumbled 93.59%.
- Bone Biologics' Accounts Payables stood at $99909.0 in 2021, then increased by 4.88% to $104786.0 in 2022, then soared by 244.19% to $360662.0 in 2023, then gained by 3.43% to $373042.0 in 2024, then climbed by 12.02% to $417884.0 in 2025.
- Business Quant data shows BBLG's Accounts Payables at $417884.0 in Q4 2025, $333081.0 in Q3 2025, and $403729.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | 88.42 Mn |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | 470.30 Mn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | 108.02 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 35.57 Mn |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Bone Biologics | 1.00 Mn | 1.00 Mn | - | 511,472.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 511,472.00 |
| Dec 31, 2025 | 417,884.00 |
| Sep 30, 2025 | 333,081.00 |
| Jun 30, 2025 | 403,729.00 |
| Mar 31, 2025 | 247,843.00 |
| Dec 31, 2024 | 373,042.00 |
| Sep 30, 2024 | 190,057.00 |
| Jun 30, 2024 | 231,872.00 |
| Mar 31, 2024 | 146,186.00 |
| Dec 31, 2023 | 360,662.00 |
| Sep 30, 2023 | 1.10 Mn |
| Jun 30, 2023 | 1.69 Mn |
| Mar 31, 2023 | 2.28 Mn |
| Dec 31, 2022 | 104,786.00 |
| Sep 30, 2022 | 799,475.00 |
| Jun 30, 2022 | 70,636.00 |
| Mar 31, 2022 | 54,913.00 |
| Dec 31, 2021 | 99,909.00 |
| Sep 30, 2021 | 70,275.00 |
| Jun 30, 2021 | 84,237.00 |